Table 5. Pooled analysis for the association between TNF-α rs1800629 polymorphism and the risk of skin cancer.

Comparison	Subgroup	Test of association				Number
		ORs	95% CIs	z	Passociation	Studies	Case	Control
A vs G	overall	1.01	0.91∼1.12	0.24	0.814	7	2710	2786
	Caucasian	1.01	0.91∼1.12	0.24	0.814	7	2710	2786
	PB	0.95	0.85∼1.07	0.82	0.413	6	2204	2271
	SBCC	1.05	0.93∼1.20	0.82	0.411	5	1817	1759
	melanoma	0.78	0.54∼1.11	1.39	0.164	1	212	211
	SSCC	1.00	0.82∼1.21	0.04	0.964	1	681	816
AA vs GG	overall	1.09	0.78∼1.54	0.52	0.603	6	2660	2726
	Caucasian	1.09	0.78∼1.54	0.52	0.603	6	2660	2726
	PB	0.88	0.60∼1.29	0.65	0.513	5	2154	2211
	SBCC	1.24	0.79∼1.95	0.95	0.340	4	1767	1699
	melanoma	0.90	0.36∼2.22	0.23	0.815	1	212	211
	SSCC	0.93	0.49∼1.77	0.23	0.818	1	681	816
GA vs GG	overall	0.99	0.88∼1.12	0.08	0.933	7	2710	2786
	Caucasian	0.99	0.88∼1.12	0.08	0.933	7	2710	2786
	PB	0.96	0.84∼1.09	0.64	0.524	6	2204	2271
	SBCC	1.03	0.89∼1.20	0.41	0.680	5	1817	1759
	melanoma	0.68	0.43∼1.06	1.72	0.086	1	212	211
	SSCC	1.01	0.80∼1.27	0.10	0.923	1	681	816
GA+AA vs GG	overall	1.00	0.89∼1.13	0.07	0.620	7	2710	2786
	Caucasian	1.00	0.89∼1.13	0.07	0.620	6	2710	2786
	PB	0.95	0.84∼1.08	0.75	0.453	5	2204	2271
	SBCC	1.05	0.91∼1.21	0.63	0.527	1	1817	1759
	melanoma	0.71	0.47∼1.08	1.62	0.105	1	212	211
	SSCC	1.00	0.80∼1.25	0.03	0.974	7	681	816
AA vs GG+GA	overall	1.10	0.79∼1.55	0.57	0.569	6	2660	2726
	Caucasian	1.10	0.79∼1.55	0.57	0.569	6	2660	2726
	PB	0.90	0.62∼1.31	0.54	0.587	5	2154	2211
	SBCC	1.23	0.79∼1.93	0.92	0.359	4	1767	1699
	melanoma	1.00	0.41∼2.44	0.01	0.991	1	212	211
	SSCC	0.92	0.49∼1.75	0.24	0.809	1	681	816
carrier A vs G	overall	1.01	0.90∼1.12	0.10	0.920	7	2710	2786
	Caucasian	1.01	0.90∼1.12	0.10	0.920	7	2710	2786
	PB	0.96	0.85∼1.09	0.59	0.553	6	2204	2271
	SBCC	1.01	0.90∼1.19	0.53	0.595	5	1817	1759
	melanoma	0.78	0.53∼1.17	1.18	0.236	1	212	211
	SSCC	1.00	0.81∼1.24	0.01	0.996	1	681	816

SBCC: skin basal cell carcinomas; SSCC: skin squamous cell carcinoma, Ors: odd ratios; CIs: confidence intervals.